Xencor | XNCR - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amgen USD 657M 4M 2026-03
Arrowhead Research USD 22.5M 811K 2025-12
AstraZeneca USD 484M 181M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 411M 21M 2026-03
Cytokinetics USD 30.33M 4.01M 2025-12
GlaxoSmithKline GBP 167M 21M 2026-03
J&J USD 43M 25M 2026-03
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
Merck USD 479M 67M 2026-03
Novartis USD 343M 39M 2026-03
Pfizer USD 711M 59M 2025-12
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Roche Holding CHF 304M 7.5M 2025-06
Xencor USD 7.35M 311K 2025-12